On May 14, 2025, Teliso-V was granted accelerated approval by the US Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic, non-squamous NSCLC with high c-Met protein OE who have received a prior systemic therapy. This evidence concerns the gene MET and non-small cell lung carcinoma.